All In Biotech

Drug Trial Radar · NCT07559370

Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria

Evaluating the Safety and Efficacy of Imatinib in Combination With Artemether and Lumefantrine for Treatment of Uncomplicated Malaria

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,116 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,116

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Victoria Biomedical Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Purdue University
First posted
Apr 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa

Conditions

  • Malaria (Plasmodium Falciparum)

Interventions

  • Artemether lumefantrine tabletsDrug

    There is no difference

  • Artemether Lumefantrine and Imatinib MesylateDrug

    There is no difference

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose of Imatinib (in mg) Required to Eliminate Viable ParasitesTime frame: 48 hours post-first dose
  2. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) by Severity GradeTime frame: Up to Day 35
  3. Number of Participants with PCR-Corrected RecrudescenceTime frame: Day 35

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Victoria Biomedical Research Institute

    Kisumu, Kenya · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.